120 related articles for article (PubMed ID: 1284786)
1. Coordinate loss of growth regulatory factors following castration of rats carrying the Dunning R3327 G prostatic tumor.
Rubenstein M; Shaw M; Targonski P; McKiel CF; Dubin A; Guinan PD
Clin Physiol Biochem; 1992; 9(2):47-50. PubMed ID: 1284786
[TBL] [Abstract][Full Text] [Related]
2. Unusual androgen sensitivity of the androgen-independent Dunning R-3327-G rat prostatic adenocarcinoma: androgen effect on tumor cell loss.
Humphries JE; Isaacs JT
Cancer Res; 1982 Aug; 42(8):3148-56. PubMed ID: 7093958
[TBL] [Abstract][Full Text] [Related]
3. Castration induces apoptosis in the ventral prostate but not in an androgen-sensitive prostatic adenocarcinoma in the rat.
Brändström A; Westin P; Bergh A; Cajander S; Damber JE
Cancer Res; 1994 Jul; 54(13):3594-601. PubMed ID: 8012987
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
Pinski J; Reile H; Halmos G; Groot K; Schally AV
Cancer Res; 1994 Jan; 54(1):169-74. PubMed ID: 7903203
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
Joseph IB; Isaacs JT
Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
[TBL] [Abstract][Full Text] [Related]
6. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of androgen-primed chemotherapy in the Dunning R3327 G model of prostatic cancer.
English HF; Heitjan DF; Lancaster S; Santen RJ
Cancer Res; 1991 Apr; 51(7):1760-5. PubMed ID: 2004359
[TBL] [Abstract][Full Text] [Related]
8. Tumor progression in serial passages of the Dunning R3327-G rat prostatic adenocarcinoma: growth rate response to endocrine manipulation.
Pollack A; Block NL; Stover BJ; Irvin GL
Cancer Res; 1985 Mar; 45(3):1052-7. PubMed ID: 3971360
[TBL] [Abstract][Full Text] [Related]
9. Castration-induced apoptosis of androgen-dependent shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins.
Nickerson T; Miyake H; Gleave ME; Pollak M
Cancer Res; 1999 Jul; 59(14):3392-5. PubMed ID: 10416600
[TBL] [Abstract][Full Text] [Related]
10. Expression of transforming growth factor-beta 1 in rat ventral prostate and Dunning R3327 PAP prostate tumor after castration and estrogen treatment.
Lindström P; Bergh A; Holm I; Damber JE
Prostate; 1996 Oct; 29(4):209-18. PubMed ID: 8876704
[TBL] [Abstract][Full Text] [Related]
11. R3327 prostate adenocarcinoma clonogenic cells: epithelial properties and hormone response.
Dibner JJ; Nakeff A
J Natl Cancer Inst; 1983 Jun; 70(6):1057-66. PubMed ID: 6574275
[TBL] [Abstract][Full Text] [Related]
12. Prostatic tumor regrowth after initially successful castration therapy may be related to a decreased apoptotic cell death rate.
Landström M; Damber JE; Bergh A
Cancer Res; 1994 Aug; 54(16):4281-4. PubMed ID: 7913874
[TBL] [Abstract][Full Text] [Related]
13. A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model.
Johansson A; Jones J; Pietras K; Kilter S; Skytt A; Rudolfsson SH; Bergh A
Prostate; 2007 Nov; 67(15):1664-76. PubMed ID: 17854058
[TBL] [Abstract][Full Text] [Related]
14. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.
Gnanapragasam VJ; Darby S; Khan MM; Lock WG; Robson CN; Leung HY
J Pathol; 2005 Jun; 206(2):205-13. PubMed ID: 15818594
[TBL] [Abstract][Full Text] [Related]
15. Functionality of estrogen receptor and tamoxifen treatment of R3327 Dunning rat prostate adenocarcinoma.
Ip MM; Milholland RJ; Rosen F
Cancer Res; 1980 Jul; 40(7):2188-93. PubMed ID: 7388787
[TBL] [Abstract][Full Text] [Related]
16. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
Joseph IB; Nelson JB; Denmeade SR; Isaacs JT
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2507-11. PubMed ID: 9815654
[TBL] [Abstract][Full Text] [Related]
17. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model.
Cheng L; Zhang S; Sweeney CJ; Kao C; Gardner TA; Eble JN
Anticancer Res; 2004; 24(4):2135-40. PubMed ID: 15330153
[TBL] [Abstract][Full Text] [Related]
18. Antitumor efficacy in rats of CGP 19984, a thiazolidinedione derivative that inhibits luteinizing hormone secretion.
Ip MM; Sylvester PW; Schenkel L
Cancer Res; 1986 Apr; 46(4 Pt 1):1735-40. PubMed ID: 3948162
[TBL] [Abstract][Full Text] [Related]
19. Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats.
Isaacs JT
Cancer Res; 1989 Nov; 49(22):6290-4. PubMed ID: 2804976
[TBL] [Abstract][Full Text] [Related]
20. Immunoregulatory markers in rats carrying Dunning R3327 H, G, or MAT-LyLu prostatic adenocarcinoma variants.
Rubenstein M; Shaw MW; McKiel CF; Ray PS; Guinan PD
Cancer Res; 1987 Jan; 47(1):178-82. PubMed ID: 3491674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
